Table 1 Clinical characteristics of the study population
Variables | Vilda | High met | p value |
|---|---|---|---|
(n = 48) | (n = 48) | ||
Age (years) | 62 (31 to 74) | 60 (20 to 74) | 0.50* |
Male sex (%) | 54.2 | 64.6 | 0.43 |
Body mass index (kg/m2) | 25.7 ± 4.1 | 26.1 ± 4.7 | 0.59 |
Flow mediated dilatation (%) | 5.5 ± 2.0 | 6.1 ± 3.0 | 0.20 |
FPG (mM/L) | 7.8 ± 1.3 | 8.1 ± 1.3 | 0.20 |
Hemoglobin A1c (%) | 7.3 (6.6 to 8.4) | 7.2 (6.4 to 8.7) | 0.23* |
SBP (mmHg) | 129.0 ± 13.0 | 126.6 ± 12.2 | 0.35 |
DBP (mmHg) | 75.0 ± 9.2 | 75.5 ± 10.2 | 0.83 |
LDL-cholesterol (mg/dL) | 112.4 ± 30.0 | 110.6 ± 28.7 | 0.76 |
Current smokers (%) | 29.2 | 27.1 | 0.90 |
Hypertension (%) | 41.7 | 43.8 | 0.89 |
Dyslipidemia (%) | 77.1 | 68.8 | 0.43 |
Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (%) | 31.3 | 27.1 | 0.81 |
Statin (%) | 39.6 | 35.4 | 0.80 |
Diabetic nephropathy (%) | 20.8 | 20.8 | 1.00 |
Metformin (mg) | 559.5 ± 107.8 | 595.2 ± 122.9 | 0.16 |
Sulfonylureas (%) | 18.8 | 27.1 | 0.65 |
Glinides (%) | 0 | 0 | 1.00 |